XML 39 R28.htm IDEA: XBRL DOCUMENT v3.24.2.u1
Revenue- Incyte Corporation (Details)
$ in Thousands
 1 Months Ended 3 Months Ended 6 Months Ended 9 Months Ended 12 Months Ended 24 Months Ended 78 Months Ended
Jun. 30, 2024
USD ($)
Mar. 31, 2023
USD ($)
Jan. 31, 2022
USD ($)
Jun. 30, 2024
USD ($)
Jun. 30, 2023
USD ($)
Jun. 30, 2024
USD ($)
Jun. 30, 2023
USD ($)
Sep. 30, 2019
Dec. 31, 2017
USD ($)
Dec. 31, 2018
USD ($)
Jun. 30, 2024
USD ($)
Dec. 31, 2023
USD ($)
Jul. 31, 2022
USD ($)
Dec. 31, 2019
USD ($)
performanceObligation
Collaboration And Other Agreements [Line Items]                            
Revenues       $ 10,797 $ 13,136 $ 19,901 $ 37,632              
Deferred revenue, current $ 23,818     23,818   23,818         $ 23,818 $ 21,651    
Deferred revenue, net of current portion 55,503     55,503   55,503         55,503 59,243    
Incyte Corporation | Incyte MGA012 Agreement                            
Collaboration And Other Agreements [Line Items]                            
Non-refundable upfront payment                 $ 150,000          
Potential commercial milestone payments under agreement                           $ 330,000
Potential development and regulatory milestone payments under agreement                           425,000
Development and regulatory milestones recognized   $ 15,000                 115,000      
Collaborative agreement transaction price                           $ 154,000
Variable consideration recognized                   $ 4,000        
Number of performance obligations | performanceObligation                           2
Gilead | Gilead First Research Program                            
Collaboration And Other Agreements [Line Items]                            
Revenues 3,300     1,300   2,000                
Deferred revenue 16,200     16,200   16,200         16,200 14,900    
Deferred revenue, current 16,200     16,200   16,200         16,200 11,800    
Deferred revenue, net of current portion                       3,100    
Minimum | Incyte Corporation | Incyte MGA012 Agreement                            
Collaboration And Other Agreements [Line Items]                            
Potential proceeds from royalties (percent)               15.00%            
Maximum | Incyte Corporation | Incyte MGA012 Agreement                            
Collaboration And Other Agreements [Line Items]                            
Potential proceeds from royalties (percent)               24.00%            
Revenues From License Agreements | Incyte Corporation | Incyte MGA012 Agreement                            
Collaboration And Other Agreements [Line Items]                            
Revenues       100 15,000 300 15,000   $ 150,000          
Revenues From License Agreements | Incyte Corporation | Incyte MGA012 Clinical Services                            
Collaboration And Other Agreements [Line Items]                            
Revenues         100 100 1,400              
Revenues From License Agreements | Incyte Corporation | Incyte Commercial Supply Agreement                            
Collaboration And Other Agreements [Line Items]                            
Revenues       400   800 100              
RevenuesFromCMOAgreementsMember | Incyte Corporation                            
Collaboration And Other Agreements [Line Items]                            
Non-refundable upfront payment     $ 10,000                      
Annual Fixed Payments     $ 14,400                      
Revenues       2,100 $ 1,600 4,300 $ 5,200              
Deferred revenue 5,200     5,200   5,200         5,200 7,000    
Deferred revenue, current $ 5,200     $ 5,200   $ 5,200         $ 5,200 $ 7,000    
RevenuesFromCMOAmendmentAgreement | Incyte Corporation                            
Collaboration And Other Agreements [Line Items]                            
Annual Fixed Payments                         $ 19,500  
Additional Payments                         $ 5,100  
Manufacturing Services | Incyte Corporation                            
Collaboration And Other Agreements [Line Items]                            
Extension term                         1 year  
Manufacturing Services | Incyte Corporation | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2022-02-01                            
Collaboration And Other Agreements [Line Items]                            
Revenue, remaining performance obligation, expected timing of satisfaction     3 years